Amgenの空売り状況は、投資家がAmgenの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Amgen (NASDAQ:AMGN) 株価情報, 空売り情報

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Inc

AMGEN ORD

A federal judge has ruled that Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) must address a proposed class-action lawsuit accusing the company of delaying disclosures regarding its potential $10.7 billion tax liability.
The case argues that shareholders were misled when Amgen allegedly concealed the risk of owing billions to the Internal Revenue Service (IRS).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41031132/amgens-rocatinlimab-has-commercial-potential-despite-competitive-landscape-says-gol" rel="noreferrer noopener">Amgen&#8217;s Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs</a>.
The Reuters report highlighted that a U.S. District Judge determined that shareholders had a reasonable basis for claiming that Amgen had acted recklessly in not revealing the size of its tax dispute.
In a March complaint filed in Manhattan federal court, a Detroit-based pension fund said&nbsp;Amgen concealed the dispute over its international tax strategy between July 2020 and April 2022 and had its investors wait too long to disclose a $10.7 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31346628/amgen-faces-lawsuit-for-hiding-its-stupendous-tax-bill-of-10b" rel="noreferrer noopener">tax and penalty bill</a>.
The judge&#8217;s ruling highlighted that Amgen&#8217;s failure to inform investors of the potential liability properly was substantial.
Despite Amgen&#8217;s defense that it had not hidden the IRS&#8217;s position and had warned about the agency&#8217;s increased scrutiny, shareholders saw significant losses following the eventual disclosures.
In its <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/318154/000031815424000035/amgn-20240630.htm" rel="noreferrer noopener">latest</a> quarterly June report, the company said the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. The&nbsp;two&nbsp;cases were consolidated in the U.S. Tax Court on December 19, 2022. The trial is currently scheduled to begin on November 4, 2024.
Price Action: AMGN stock is down 0.84% at $317.64 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41146507/apples-iphone-16-series-leads-growth-but-high-end-model-preference-declines-analyst" target="_blank" rel="noreferrer noopener">Apple&#8217;s iPhone 16 Series Leads Growth, But High-End Model Preference Declines: Analyst</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

News

Health Care

Legal

General

AMGN

Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has risen 6.33% since its last report. The company recently reported that it has 9.00 million shares sold short, which is 1.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717425_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(AMGN) - Analyzing Amgen's Short Interest

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight rating and announces Price Target of $405.

Price Target

Initiation

Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Amgen with Overweight Rating, Announces Price Target of $405

RBC Capital analyst Gregory Renza reiterates Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Outperform and maintains $362 price target.

Reiteration

RBC Capital Reiterates Outperform on Amgen, Maintains $362 Price Target

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/09/25/final-trades-trane-tech-american-tower-regeneron-and-taiwan-semi.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/government/24/09/41007184/taiwan-semi-secures-7-5b-boost-for-arizona-expansion-aims-for-advanced-chip-production-report">cheap</a>.
On Monday, Taiwan Semiconductor Manufacturing bagged the government's approval for an additional $7.5 billion infusion into Taiwan Semiconductor Arizona unit, the Taipei Times cited the Department of Investment Review statement.
Amy Raskin of Chevy Chase Trust named Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals' effort to prevent the sale of Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Eylea biosimilar. Regeneron filed a notice of its appeal to the U.S. Court of Appeals <a href="https://www.benzinga.com/general/biotech/24/09/41012464/why-is-regeneron-pharmaceuticals-stock-trading-lower-on-tuesday">for the Federal Circuit</a>.
 Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kari Firestone of Aureus Asset Management picked American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) as her final trade.
On Sept. 23, JP Morgan analyst Philip Cusick maintained American Tower with an Overweight rating and raised the price target from $240 to $250.
Joseph M. Terranova of Virtus Investment Partners named Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>).
On July 31, Trane Technologies reported better-than-expected second-quarter financial results and raised its FY24 guidance. Revenues grew 13% Y/Y to $5.31 billion, surpassing the consensus of $5.13 billion. Bookings increased 19% Y/Y to$5.34 billion in the quarter. Adjusted EPS of $3.30 surpassed the street view of $3.08.
Price Action:
<ul>
<li>Taiwan Semiconductor gained 0.2% to close at $182.35 during Wednesday's session.</li>
<li>Regeneron Pharmaceuticals shares fell 1.4% to settle at $1,031.15 on Wednesday.</li>
<li>American Tower fell 0.4% to close at $235.63 during Wednesday's session.</li>
<li>Trane Technologies shares gained 1% to close at $387.70 on Wednesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

REGN

Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'

Ratings for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381.00, and a low estimate of $215.00. Witnessing a positive shift, the current average has risen by 2.31% from the previous average price target of $319.00.
<img src="https://www.benzinga.com/files/images/story/2024/1727287290_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Amgen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Yaron Weber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$381.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$305.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$330.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$362.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$335.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$303.00</td>
<td>$310.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amgen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amgen compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Amgen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Amgen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amgen analyst ratings.</a>
<h2>Discovering Amgen: A Closer Look</h2>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Understanding the Numbers: Amgen's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Amgen's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 20.07%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.89% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amgen's ROE excels beyond industry benchmarks, reaching 13.63%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.81%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 10.57, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Amgen's Future

In an investor update on Tuesday,&nbsp;Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).
HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41022603/amgens-rocatinlimab-data-beats-placebo-in-atopic-dermatitis-trial-but-analyst-says-" rel="noreferrer noopener">in 726 patients</a>.
Amgen&nbsp;<a target="_blank" href="https://investors.amgen.com/static-files/a7119a35-06de-497e-ba75-146404c54d95" rel="noreferrer noopener">reported</a> that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.
Amgen stock is trading lower as the data seemed to be below expectations.
Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent, the analyst still sees strong commercial potential for the drug (if approved).
This is due to its favorable safety and tolerability profile, convenient dosing schedule, and the substantial total addressable market for atopic dermatitis, even with the high level of competition in the space, including Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Ebglyss (lebrikizumab) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)&nbsp;amlitelimab.
The analysts view the recent updates as encouraging but note that the stock still doesn&#8217;t fully reflect the potential value of either asset.
The firm models peak sales for rocatinlimab in atopic dermatitis to reach around $4 billion by 2035 (with a 60% probability of success).
While not included in the model, the analyst sees a significant opportunity for Uplizna in generalized myasthenia gravis, estimating potential sales of about $2 billion.
Goldman Sachs maintains the Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/AMGN/analyst-ratings" rel="noreferrer noopener">price target of $370</a>.
Looking ahead, attention shifts to Amgen&#8217;s Phase 2 obesity data expected by the end of the year, where positive outcomes could lead to a stock re-rating to account for revenue potential and ease concerns about the upcoming loss of exclusivity in the <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40229568/amgens-mixed-q2-results-highlight-obesity-drug-potential-analysts-focus-shifts-to-u" rel="noreferrer noopener">latter half of the decade</a>.
Earlier this year, Amgen had the data from animal and early-stage human trials of its experimental obesity drug AMG 133 (maridebart cafraglutide)&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37318123/amgens-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-g" rel="noreferrer noopener">published in Nature Metabolism</a>.
The Journal confirmed the GIPR antagonist and GLP-1R agonist activities in cell-based systems and reported the ability of AMG 133 to reduce body weight and improve metabolic markers in male obese&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">mice and cynomolgus monkeys</a>.&nbsp;
Price Action: AMGN stock is down 4.67% at $315.47 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41029568/masimo-names-interim-ceo-as-activist-board-members-step-in-joe-kiani-exits-amid-legal-clash" target="_blank" rel="noreferrer noopener">Masimo Names Interim CEO As Activist Board Members Step In; Joe Kiani Exits Amid Legal Clash</a>.</li>
</ul>

Analyst Color

Equities

Movers

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs

Baird analyst Brian Skorney reiterates Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Underperform and maintains $215 price target.

Baird Reiterates Underperform on Amgen, Maintains $215 Price Target

WIIM

Amgen shares are trading lower after following atopic dermatitis data, which some analysts noted did not meet expectations amid competition in the market.

In an investor update on Tuesday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).
HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients.
Amgen <a target="_blank" href="https://investors.amgen.com/static-files/a7119a35-06de-497e-ba75-146404c54d95" rel="noreferrer noopener">reported</a> that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.
<ul>
<li>32.8% of rocatinlimab-treated subjects achieved an EASI-75 response at week 24 vs. 13.7% placebo.</li>
<li>19.3% of rocatinlimab-treated subjects achieved a vIGA-AD 0/1 response at week 24 vs. 6.6% placebo.</li>
<li>16.4% of rocatinlimab-treated subjects achieved a rIGA 0/1 response at week 24 vs. 4.9% placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40229568/amgens-mixed-q2-results-highlight-obesity-drug-potential-analysts-focus-shifts-to-u" rel="noreferrer noopener">Amgen&#8217;s Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts</a>.
MINT Phase 3 trial of Uplizna in generalized myasthenia gravis showed a clinically meaningful and statistically significant MG-ADL (Myasthenia Gravis Activities of Daily Living) score, a measure of the severity of myasthenia gravis symptoms.
After two doses of Uplizna, MG-ADL score showed an overall improvement of -4.2, versus -1.9 placebo adjusted.
The trial demonstrated a statistically significant improvement in the Quantitative Myasthenia Gravis (QMG) score, a clinical assessment that measures the severity of myasthenia gravis.
QMG score improvement with Uplizna compared to placebo at week 26 was -4.8 overall improvement compared to -2.5 placebo adjusted.
No new safety signals were identified.
STAT News <a target="_blank" href="https://www.statnews.com/2024/09/24/amgen-success-trials-eczema-rocatinlimab-myasthenia-gravis-uplizna-competition-remains-stiff/" rel="noreferrer noopener">noted</a> that though the trials succeeded, the therapies did not beat existing competitors on the market.
51% of adults <a target="_blank" href="https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/easi-clinical-trial" rel="noreferrer noopener">treated</a> with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)/ Regeneraon Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) achieved EASI-75 vs.&nbsp;15%&nbsp;with placebo at Week 16 in SOLO 1 trial and 44% vs. 12% in SOLO 2 trial.
William Blair noted that rocatinlimab&#8217;s data fell short of expectations, raising concerns about how its clinical profile stacks up in the increasingly competitive atopic dermatitis market, particularly as the broader ROCKET program unfolds.
On the other hand, the Uplizna results for myasthenia gravis exceeded William Blair&#8217;s expectations, indicating a strong market potential for the treatment. Key advantages include its less frequent dosing and potential to reduce steroid use.
The focus will be determining Uplizna&#8217;s position within the myasthenia gravis treatment landscape alongside other options like FcRn, IVIg, complement inhibitors, rituximab, and more. Additionally, the potential for Uplizna&#8217;s CD19-targeting strategy in autoimmune diseases will be closely watched, especially with competitors like Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>).
Price Action: AMGN stock is trading lower by 2.09% to $324.04 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41021471/private-equity-firms-circle-sanofis-consumer-health-business-amid-potential-spinoff" target="_blank" rel="noreferrer noopener">Private Equity Firms Circle Sanofi&#8217;s Consumer Health Business Amid Potential Spinoff</a>.</li>
</ul>
Photo via Shutterstock

CGEM

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

The primary endpoint in the trial was met, as 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with placebo (11%; p&lt;0.0001) at week 24. The safety profile was consistent with the complete body of clinical data supporting TEPEZZA.3 A second Phase 3 clinical trial is ongoing in Japan evaluating TEPEZZA among adults with chronic TED and a low CAS (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262367-1&amp;h=1144576111&amp;u=https%3A%2F%2Fjrct.niph.go.jp%2Flatest-detail%2FjRCT2031220730&amp;a=jRCT2031220730">jRCT2031220730</a>).

Global

Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS

Amgen Executive Says Experimental Drug Rocatinlimab Met Primary Endpoints In Late-Stage Study

Amgen's TEPEZZA Approved In Japan For Active Thyroid Eye Disease

Chief District Judge Thomas Kleeh <a href="https://www.courtlistener.com/docket/68435952/in-re-aflibercept-patent-litigation/?filed_after=&amp;filed_before=&amp;entry_gte=&amp;entry_lte=&amp;order_by=desc#entry-343">denied</a> Regeneron Pharmaceuticals, Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) effort to prevent the sale of Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Eylea biosimilar.
Regeneron filed a notice of its appeal to the U.S. Court of Appeals for the Federal Circuit.
The <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/InReAfliberceptPatentLitigationDocketNo124md03103NDWVaApr112024Co/9?doc_id=X5Q74042K7G9TGAR2GDOLU0DNF6" rel="noreferrer noopener">appeal </a>is from the Order issued on September 23, 2024, which denied Regeneron&#8217;s request for a preliminary injunction, along with any related orders, decisions, rulings, findings, or conclusions connected to that Order.
Reuters highlighted that an Amgen spokesperson expressed the company&#8217;s satisfaction with the decision. Amgen will reveal the timeline for launching its biosimilar Pavblu &#8220;in due course.&#8221;
Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea. The lawsuit claims the infringement of over 30 patents, which the pharma claims will &#8220;irreparably&#8221; harm its business if Amgen is not &#8220;enjoined&#8221; from violating these protections.
The lawsuit also <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/egpbakxeavq/REGENERON%20AMGEN%20LAWSUIT%20complaint.pdf" rel="noreferrer noopener">notes</a>, &#8220;Amgen&#8217;s commercial manufacture, use, offer for sale, and/or sale within the United States, or importation into the United States, of ABP 938 before the expiration of the '106 patent will cause Regeneron injury, entitling Regeneron to damages and/or other monetary relief.&#8221;
In October 2023, Amgen said the FDA <a target="_blank" href="https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-financial-results" rel="noreferrer noopener">accepted</a> its abbreviated Biologics Drug Application for ABP 938, a biosimilar copy of Eylea.
Stat News <a target="_blank" href="https://www.statnews.com/2024/09/24/regeneron-eylea-biosimilar-amgen-fight-heats-up/" rel="noreferrer noopener">noted</a> that the judge&#8217;s decision came as a surprise, given that this same judge had previously approved Regeneron&#8217;s requests for injunctions against other pharmaceutical companies attempting to release Eylea biosimilars.
In December, a court ruling found that Viatris Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) replica of Regeneron&#8217;s Eylea <a href="https://www.benzinga.com/general/biotech/23/12/36408741/regeneron-celebrates-legal-win-court-upholds-eylea-medication-patent" target="_blank" rel="noreferrer noopener">violated patent rights</a>.
Price Action: REGN stock is down 6% at $1,025.44 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41010674/diamondback-energy-kinetik-strengthen-stake-in-epic-crude-with-new-deal-and-long-term-commitment" target="_blank" rel="noreferrer noopener">Diamondback Energy, Kinetik Strengthen Stake In EPIC Crude With New Deal And Long-Term Commitments</a>.</li>
</ul>

VTRS

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?

Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 43% bullish and 43%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $1,298,955, and 6 are calls, for a total amount of $312,382.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $145.0 to $390.0 for Amgen over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Amgen stands at 388.45, with a total volume reaching 3,084.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amgen, situated within the strike price corridor from $145.0 to $390.0, throughout the last 30 days.
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727200853_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$20.5</td>
<td>$19.95</td>
<td>$20.03</td>
<td>$330.00</td>
<td>$801.2K</td>
<td style="text-align: right;">590</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$20.15</td>
<td>$20.0</td>
<td>$20.05</td>
<td>$330.00</td>
<td>$188.3K</td>
<td style="text-align: right;">590</td>
<td style="text-align: right;">538</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$190.8</td>
<td>$186.9</td>
<td>$188.7</td>
<td>$145.00</td>
<td>$132.0K</td>
<td style="text-align: right;">40</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.85</td>
<td>$6.85</td>
<td>$7.3</td>
<td>$360.00</td>
<td>$70.0K</td>
<td style="text-align: right;">109</td>
<td style="text-align: right;">96</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$4.1</td>
<td>$3.8</td>
<td>$4.1</td>
<td>$335.00</td>
<td>$52.4K</td>
<td style="text-align: right;">235</td>
<td style="text-align: right;">265</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>With a trading volume of 737,520, the price of AMGN is down by -0.96%, reaching $332.39.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Market Whales and Their Recent Bets on AMGN Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Amgen.
Looking at options history for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $232,384 and 6, calls, for a total amount of $241,377.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $340.0 for Amgen over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $280.0 to $340.0 in the last 30 days. 
<h3>Amgen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727102741_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.3</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$330.00</td>
<td>$133.9K</td>
<td>462</td>
<td style="text-align: right;">330</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$24.45</td>
<td>$23.55</td>
<td>$24.35</td>
<td>$340.00</td>
<td>$61.0K</td>
<td>1.2K</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$60.35</td>
<td>$58.75</td>
<td>$58.75</td>
<td>$280.00</td>
<td>$41.1K</td>
<td>82</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$27.45</td>
<td>$26.6</td>
<td>$26.6</td>
<td>$330.00</td>
<td>$39.9K</td>
<td>1.1K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$26.75</td>
<td>$26.35</td>
<td>$26.35</td>
<td>$330.00</td>
<td>$39.5K</td>
<td>1.1K</td>
<td style="text-align: right;">43</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Amgen Standing Right Now?</h3>
<ul>
<li>With a trading volume of 158,874, the price of AMGN is down by -0.24%, reaching $336.58.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About Amgen

Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $201,232, and 2 are calls, for a total amount of $119,247.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $280.0 to $370.0 for Amgen over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $280.0 to $370.0 over the preceding 30 days.
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726772744_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.55</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$370.00</td>
<td>$78.2K</td>
<td style="text-align: right;">649</td>
<td style="text-align: right;">80</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$7.1</td>
<td>$5.55</td>
<td>$6.3</td>
<td>$335.00</td>
<td>$48.5K</td>
<td style="text-align: right;">628</td>
<td style="text-align: right;">46</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$59.45</td>
<td>$58.55</td>
<td>$58.55</td>
<td>$280.00</td>
<td>$40.9K</td>
<td style="text-align: right;">89</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$14.3</td>
<td>$14.2</td>
<td>$14.2</td>
<td>$315.00</td>
<td>$39.7K</td>
<td style="text-align: right;">607</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$3.45</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$332.50</td>
<td>$32.5K</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>Currently trading with a volume of 759,929, the AMGN's price is up by 1.08%, now at $336.52. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 40 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Amgen's Latest Options Trends

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGN

EXAS

ILMN

MRNA

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reportedly announced on Tuesday that it will remove AbbVie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
This move is part of a larger trend in the U.S. pharmaceutical market, as health plans seek to cut costs by promoting alternatives to high-priced drugs.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth</a>.
Reuters highlights that Amgen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Amjevita, managed by its pharmacy benefits unit, Optum Rx, is among the biosimilars covered under UnitedHealth&#8217;s lists for commercial health plans.
With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira.
Cigna Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) announced last month that it would remove Humira from some of its lists in 2025, following a similar decision by CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark unit in April.
CVS&#8217;s action led to a swift shift, with more patients transitioning to Sandoz Group AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>) biosimilar version of Humira in just three weeks than in the previous 15 months combined.
Cigna plans to cover biosimilars like Boehringer Ingelheim&#8217;s Cyltezo, Simlandi from Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and Alvotech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) products, including an unbranded version of Sandoz&#8217;s Hyrimoz, as replacements for Humira.
UnitedHealth noted that patients would still have access to Humira until the FDA designates the preferred biosimilars as interchangeable with the original drug, per the report. The FDA is expected to make this designation in 2025.
Despite the growing competition, AbbVie has managed to retain a dominant share of the U.S. Humira market throughout 2023. This has been achieved through favorable negotiations with PBMs, even as biosimilar alternatives from companies like Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) entered the market.
As per a Reuters report, Humira has still managed to retain over 80% of its patients even after facing lower-priced rivals in the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38468317/arthritis-patients-cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost" rel="noreferrer noopener">U.S. over the past year</a>.
Following their launch last year, pharmacy benefit managers largely influenced patient access, with minimal incentive for doctors to switch to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39228916/abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-" rel="noreferrer noopener">these alternatives</a>.
In May, Cantor Fitzgerald said AbbVie had positioned itself to absorb Humira biosimilar erosion and achieve modest <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38899905/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst" rel="noreferrer noopener">operational revenue growth</a>.
Price Action: UNH stock is down 2% at $587.07 at last check Wednesday.
Photo via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40817991/gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-" target="_blank" rel="noreferrer noopener">GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech</a>.</li>
</ul>

ABBV

ALVO

SDZNY

SDZXF

TEVA

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars

Shares of Terns Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tern#NASDAQ">TERN</a>), a clinical-stage company, soared 16.8% after the company announced positive top-line data from the early-stage single and multiple-ascending dose (SAD and MAD) obesity study. The phase I study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of its investigational, oral, small-molecule&nbsp;GLP-1R agonist, TERN-601, dosed once daily in healthy adults with obesity or overweight.
<h2>Terns Reports Superior Weight Reduction With TERN-601</h2>
Per the data readout from the phase I obesity study, treatment with TERN-601 led to dose-dependent, statistically significant placebo-adjusted mean weight loss across all three doses (240 mg, 500 mg and 740 mg) evaluated in the 28-day MAD study.
The maximum placebo-adjusted mean weight loss of 4.9% was observed at the highest dose of TERN-601 (740 mg), administered once daily. It was also observed that 67% of the patients treated with the candidate, lost 5% or more of their baseline body weight at the 740 mg dosage strength of TERN-601.
Additionally, Terns Pharmaceuticals reported that the candidate was generally safe and overall well-tolerated in the phase I obesity study. Despite fast titration to high doses, no treatment-related dose interruptions, reductions or discontinuations at any dose strength were observed. Treatment-related adverse events were mostly mild to moderate in severity. Importantly, no clinically meaningful changes in liver enzymes, vital signs or electrocardiograms were observed.
Year to date, shares of TERN have jumped 40.5% against the industry&#39;s 1.6% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a9/77177.jpg?v=1148197964" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
Based on such encouraging results, TERN believes that TERN-601 has the potential to be a class-leading GLP-1R agonist for weight management. The candidate&#39;s distinct properties, like low solubility and high gut permeability, could result in a prolonged duration of efficacy thatmay be advantageous as an oral GLP-1R agonist.
<h2>Terns&#39; Future Plans for TERN-601 in Weight Management</h2>
Per management, the positive results from the phase I study underscore the potential of TERN-601 to be developed for treating obesity as a monotherapy or in combination with other agents. Terns Pharmaceuticals expects to initiate a phase II study of TERN-601 for the obesity indication in 2025.
The company stated that it has already successfully identified an optimal range of clinically active, well-tolerated doses for phase II development and does not anticipate any new dose range exploration.
<div class="chart_embed">
<h2>Terns Pharmaceuticals, Inc. Price and Consensus</h2>
<img alt="Terns Pharmaceuticals, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ba/1725977062.png" style="height:310px; width:600px" title="" />
Terns Pharmaceuticals, Inc. price-consensus-chart | Terns Pharmaceuticals, Inc. Quote
</div>
<h2>Other Players Operating in the Obesity Market</h2>
The obesity market is currently dominated by two large drugmakers, Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) and Novo Nordisk (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>),&nbsp;with their respective obesity drugs Zepbound and Wegovy. Despite having approved drugs in this space, LLY and NVO have been unable to cope with existing demand.
Eli Lilly launched its obesity drug, Zepbound,a dual GIP and GLP-1R agonist in November 2023. Zepbound has seen a strong uptake since its launch. The drug generated revenues of $1.76 billion in the first half of 2024.
On the other hand, Wegovy, a GLP-1 agonist, is NVO&#39;s blockbuster chronic weight management injection approved for adults with obesity or overweight. The drug received FDA approval in 2021 and has witnessed stellar performance ever since. In the first half of 2024, Wegovy sales generated DKK 21 billion in revenues.
Amgen&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amgn#NASDAQ">AMGN</a>) is also developing MariTide (maridebart cafraglutide), a GIPR/GLP-1 receptor for obesity in its pipeline. In May, Amgen stated that it was &quot;very encouraged&quot; by the interim data from the phase II study on MariTide. Top-line 52-week data from the phase II study on MariTide in adults with overweight or obesity is expected in late 2024. AMGN is planning to conduct a comprehensive phase III program on the candidate across obesity, obesity-related conditions and type-II diabetes.
Per research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $130 billion by 2030. This is also evident from the fact that Lilly and Novo Nordisk are investing heavily to optimize their production capacities and have started evaluating multiple other novel obesity candidates.
<h2>Zacks Rank</h2>
Terns Pharmaceuticals currently carries a Zacks Rank #2 (Buy).
<a href="https://www.zacks.com/stock/news/2334185/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334185">To read this article on Zacks.com click here.</a>

Small Cap

TERN

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet

Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report

Lilly looking to test Zepbound as health maintenance drug: report

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big gains. Keep reading… The biotech sector is rapidly expanding due to the rising global demand for therapeutics, and the development, manufacturing, and commercialization of medicines for various diseases, such as cancer and neurodegenerative disorders. This dynamic landscape presents savvy investors with opportunities to capitalize on significant profit potential.
In this favorable environment, investors might consider investing in fundamentally strong biotech stocks like Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), and Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>) for potential substantial gains.
The biotech sector targets new and rare diseases, emphasizing innovative vaccines and therapies. The increasing incidence of various illnesses demands greater R&amp;D investments and advancements in biotechnology to enhance prevention and treatment across all age groups. This growing demand for personalized medicine, coupled with supportive government initiatives, significantly boosts sales in the biotech industry.
Consequently, the global biotechnology market is projected to reach $3.88 trillion by 2030, growing at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>. Notably, the future of biotech appears promising, driven by sophisticated innovations such as gene editing, CRISPR diagnostics, bioprinting, and tissue engineering. Moreover, the integration of AI enhances accessibility and affordability, instilling optimism in the biotech sector's potential.
Furthermore, investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 36% returns over the past year. Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/haematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its product portfolio includes Enbrel, Neulasta, Prolia, and Xgeva.
On June 6, 2024, AMGN announced FDA approval of BLINCYTO for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase. This marks the third indication for BLINCYTO and demonstrated superior overall survival versus chemotherapy alone.
On August 20, 2024, AMGN announced that Otezla (apremilast) is now available in the U.S. for treating moderate to severe plaque psoriasis in children and adolescents aged 6-17. It is the first FDA-approved oral treatment for this condition in this age group.
AMGN's trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a> of 63.41% is 10.6% higher than the industry average of 57.35%. Likewise, its trailing-12-month EBIT margin and levered FCF margin of 20.99% and 9.74% are 628% and 492.5% higher than the industry averages of 2.88% and 1.64%, respectively.
During the fiscal second quarter, which ended on June 30, 2024, AMGN's total revenues and non-GAAP operating income increased by 20.1% and 10.2% year-over-year, reaching $8.39 billion and $3.87 billion, respectively. Moreover, its non-GAAP net income grew marginally compared to the previous year, reaching $2.69 billion. Also, its non-GAAP earnings per share was $4.97.
Analysts expect AMGN's revenue for the quarter ending September 30, 2024, to increase 23.3% year-over-year to $8.51 billion. Its EPS for the same quarter is expected to grow 3.7% year-over-year to $5.14. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 25.4%, closing the last trading session at $335.61.
AMGN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
AMGN has a B grade for Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #17 out of 335 stocks. <a href="https://stocknews.com/stock/AMGN/">Click here</a> for the additional POWR Ratings of AMGN (Growth, Value, Momentum, Stability, and Sentiment).
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection, Dupixent injection, Libtayo injection, Praluent injection, REGEN-COV for COVID-19, and Kevzara solution.
On September 13, 2024, REGN and Sanofi announced that the FDA approved Dupixent for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps (CRSwNP). Dupixent is now the first and only treatment available for this age group with inadequately controlled CRSwNP.
On August 26, 2024, REGN announced that the European Commission approved Ordspono (odronextamab) for treating relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. This is REGN's first bispecific antibody approval, offering an off-the-shelf treatment option with the potential for complete remission.
In terms of the trailing-12-month levered FCF margin, REGN's 15.50% is significantly higher than the 1.64% industry average. Similarly, its 30.14% trailing-12-month EBIT margin is 945.6% higher than the 2.88% industry average. Moreover, its 5.50% trailing-12-month Capex / Sales is 65.5% higher than the industry average of 3.32%.
In the fiscal second quarter, which ended on June 30, 2024, REGN's revenues amounted to $3.55 billion indicating a 12.3% increase year-over-year. Likewise, the company's non-GAAP net income rose 14.3% from the year-ago value to $1.35 billion, while its non-GAAP net income per share grew 12.9% year-over-year to $11.56.
Street expects REGN's EPS and revenue for the quarter ending September 30, 2024, to increase 1.5% and 8.7% year-over-year to $11.76 and $3.66 billion, respectively. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 32.4%, closing the last trading session at $1,091.98.
REGN's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It has a B grade for Value and Quality. Within the same industry, it is ranked #9. Beyond what we stated above, we also have given REGN grades for Growth, Momentum, Stability, and Sentiment. Get all the REGN ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
Stock #1: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Asia, and internationally.
On August 22, 2024, BIIB and Eisai announced that their Alzheimer's drug Leqembi (lecanemab) was authorized for early Alzheimer's treatment in Great Britain. It is the first medicine in Europe targeting the underlying cause of Alzheimer's disease to be approved.
In terms of the trailing-12-month EBITDA margin, BIIB's 28.22% is 331.2% higher than the 6.54% industry average. Likewise, its 76.45% trailing-12-month gross profit margin is 33.3% higher than the 57.35% industry average. In addition, its 13.09% trailing-12-month levered FCF margin is 696.4% higher than the 1.64% industry average.
For the fiscal second quarter (ended June 30, 2024), BIIB's total revenue increased marginally year-over-year to $2.46 billion. Its non-GAAP net income attributable for the quarter amounted to $770.90 million, or $5.28 per share, up 31.9% and 31.3%, respectively, from the same period last year. Additionally, its free cash flow rose 42.4% year-over-year to $592.30 million.
For the quarter ending December 31, 2024, BIIB's EPS and revenue are expected to increase 14.7% and 2.4% year-over-year to $3.38 and $2.44 billion, respectively. BIIB surpassed the EPS estimates in three of the trailing four quarters. Over the past month, the stock has declined 4.5% to close the last trading session at $195.81.
It's no surprise that BIIB has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It is ranked #7 in the Biotech industry. It has an A grade for Value and a B for Growth. <a href="https://stocknews.com/stock/BIIB/">Click here</a> to see BIIB's Momentum, Stability, Sentiment, and Quality ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $332.28 per share on Tuesday afternoon, down $3.33 (-0.99%). Year-to-date, AMGN has gained 17.91%, versus a 20.81% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/amgn-regn-biib-3-biotech-stocks-that-could-deliver-big-gains/>3 Biotech Stocks That Could Deliver Big Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks That Could Deliver Big Gains

U.S. tweaks 2025 Medicare price negotiation process

Amgen (AMGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from Jefferies...

Buy Rating Affirmed: Amgen's Strategic Advancements in Obesity Drug Pipeline

Arrowhead: A First Approval Likely - Jury Still Out On Investment Opportunity

DBS analyst Nico Chen has maintained their bullish stance on AMGN stock, giving a Buy rating on October 2. Nico Chen's rating is based on the combi...

Robust Portfolio and Strategic Growth Initiatives Justify Buy Rating for Amgen with a $310 Target Price

Buy 2 October Dogs Of The Dow And Watch 5 More

AMZN

ARWR

BIIB

CSCO

GPCR

INTC

IONS

MSFT

RHHBY

TKPHF

VKTX

Earnings

Press Releases

AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS

AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE

TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE

NASDAQ: AMGN Lawsuit Notice: Investors in shares of Amgen Inc. (NASDAQ: AMGN) should contact the Shareholders Foundation

LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE

Comments

Amgen

空売り

Amgen (NASDAQ:AMGN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル